About Epizyme, an Ipsen Company

On August 12, 2022, Epizyme was acquired by Ipsen, expanding Ipsen’s oncology portfolio. Epizyme now operates as an Ipsen company with a shared goal of delivering innovative treatment options to underserved patients.

Latest News

Join Us

We are always looking for like-minded and dynamic individuals to join our team. Join the ranks of seasoned scientists, R&D and business professionals excited about executing on our vision.